Javascript must be enabled to continue!
Opioid Receptors on Bulbospinal Respiratory Neurons Are Not Activated During Neuronal Depression by Clinically Relevant Opioid Concentrations
View through CrossRef
Opioids depress the activity of brain stem respiratory-related neurons, but it is not resolved whether the mechanism at clinical concentrations consists of direct neuronal effects or network effects. We performed extracellular recordings of discharge activity of single respiratory neurons in the caudal ventral respiratory group of decerebrate dogs, which were premotor neurons with a likelihood of 90%. We used multibarrel glass microelectrodes, which allowed concomitant highly localized picoejection of opioid receptor agonists or antagonists onto the neuron. Picoejection of the μ receptor agonist [d-Ala2, N-Me-phe4, gly-ol5]-enkephalin (DAMGO, 1 mM) decreased the peak discharge frequency (mean ± SD) of expiratory neurons to 68 ± 22% ( n = 12), the δ1 agonist d-Pen2,5-enkephalin (DPDPE, 1 mM) to 95 ± 11% ( n = 15), and δ2 receptor agonist [d-Ala2] deltorphin-II to 86 ± 17% (1 mM, n = 15). The corresponding values for inspiratory neurons were: 64 ± 12% ( n = 11), 48 ± 30% ( n = 12), and 75 ± 15% ( n = 11), respectively. Naloxone fully reversed these effects. Picoejection of morphine (0.01–1 mM) depressed most neurons in a concentration dependent fashion to maximally 63% ( n = 27). Picoejection of remifentanil (240–480 nM) did not cause any significant depression of inspiratory ( n = 11) or expiratory neurons ( n = 9). 4. Intravenous remifentanil (0.2–0.6 μg·kg−1·min−1) decreased neuronal peak discharge frequency to 60 ± 12% (inspiratory, n = 7) and 58 ± 11% (expiratory, n = 11). However, local picoejection of naloxone did not reverse the neuronal depression. Our data suggest that μ, δ1, and δ2 receptors are present on canine respiratory premotor neurons. Clinical concentrations of morphine and remifentanil caused no local depression. This lack of effect and the inability of local naloxone to reverse the neuronal depression by intravenous remifentanil suggest that clinical concentrations of opioids produce their depressive effects on mechanisms upstream from respiratory bulbospinal premotor neurons.
American Physiological Society
Title: Opioid Receptors on Bulbospinal Respiratory Neurons Are Not Activated During Neuronal Depression by Clinically Relevant Opioid Concentrations
Description:
Opioids depress the activity of brain stem respiratory-related neurons, but it is not resolved whether the mechanism at clinical concentrations consists of direct neuronal effects or network effects.
We performed extracellular recordings of discharge activity of single respiratory neurons in the caudal ventral respiratory group of decerebrate dogs, which were premotor neurons with a likelihood of 90%.
We used multibarrel glass microelectrodes, which allowed concomitant highly localized picoejection of opioid receptor agonists or antagonists onto the neuron.
Picoejection of the μ receptor agonist [d-Ala2, N-Me-phe4, gly-ol5]-enkephalin (DAMGO, 1 mM) decreased the peak discharge frequency (mean ± SD) of expiratory neurons to 68 ± 22% ( n = 12), the δ1 agonist d-Pen2,5-enkephalin (DPDPE, 1 mM) to 95 ± 11% ( n = 15), and δ2 receptor agonist [d-Ala2] deltorphin-II to 86 ± 17% (1 mM, n = 15).
The corresponding values for inspiratory neurons were: 64 ± 12% ( n = 11), 48 ± 30% ( n = 12), and 75 ± 15% ( n = 11), respectively.
Naloxone fully reversed these effects.
Picoejection of morphine (0.
01–1 mM) depressed most neurons in a concentration dependent fashion to maximally 63% ( n = 27).
Picoejection of remifentanil (240–480 nM) did not cause any significant depression of inspiratory ( n = 11) or expiratory neurons ( n = 9).
4.
Intravenous remifentanil (0.
2–0.
6 μg·kg−1·min−1) decreased neuronal peak discharge frequency to 60 ± 12% (inspiratory, n = 7) and 58 ± 11% (expiratory, n = 11).
However, local picoejection of naloxone did not reverse the neuronal depression.
Our data suggest that μ, δ1, and δ2 receptors are present on canine respiratory premotor neurons.
Clinical concentrations of morphine and remifentanil caused no local depression.
This lack of effect and the inability of local naloxone to reverse the neuronal depression by intravenous remifentanil suggest that clinical concentrations of opioids produce their depressive effects on mechanisms upstream from respiratory bulbospinal premotor neurons.
Related Results
Metabolically induced neuronal differentiation
Metabolically induced neuronal differentiation
In recent years, several neuronal differentiation protocols were published that circumvent the requirement of embryoid body (EB) formation under serum-deprivation and simplified me...
Astrocytes improve neuronal health after cisplatin treatment through mitochondrial transfer
Astrocytes improve neuronal health after cisplatin treatment through mitochondrial transfer
AbstractNeurodegenerative disorders, including chemotherapy-induced cognitive impairment, are associated with neuronal mitochondrial dysfunction. Cisplatin, a commonly used chemoth...
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
<p dir="ltr">Background</p><p dir="ltr">Prolonged exposure to stressors without sufficient recovery can lead to physical and mental symptoms. In Sweden, individua...
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
<p dir="ltr">Background</p><p dir="ltr">Prolonged exposure to stressors without sufficient recovery can lead to physical and mental symptoms. In Sweden, individua...
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
ABSTRACT
Opioid addiction is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative af...
Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery
Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery
OBJECTIVE:
To assess whether a multiphase, departmental quality improvement effort decreases opioid prescribing and increases multimodal analgesic use after cesarean de...
Impact of continuous infusions of opioids on discharge opioid prescriptions
Impact of continuous infusions of opioids on discharge opioid prescriptions
Introduction: The 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep guidelines from the Society of Critical Care Medicine recommend opioids as a first-line treatment o...
Abstract 4360: Opioid, non-opioid, and non-pharmacological pain management in patients with a history of cancer
Abstract 4360: Opioid, non-opioid, and non-pharmacological pain management in patients with a history of cancer
Abstract
Background Pain is highly prevalent among individuals with cancer. Consequently, adequate and equitable pain management are hallmarks of quality cancer care...

